Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains
Tuberculosis (TB) has been a major public health problem worldwide, and the Bacillus Calmette-Guérin (BCG) vaccine is the only available vaccine against this disease. The BCG vaccine is no longer a single organism; it consists of diverse strains. The early-shared strains of the BCG vaccine are stron...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2022-12, Vol.18 (1), p.1989913-1989913 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1989913 |
|---|---|
| container_issue | 1 |
| container_start_page | 1989913 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 18 |
| creator | da Silva, Andreon Santos Machado Albuquerque, Lawrence Henrique Paz de Ponte, Carlos Germano Garrido de Almeida, Matheus Rogério de Faria, Sandra Elizabete Ribeiro Ribeiro, Mariana da Silva Pereira, Evelyn Nunes Goulart da Silva Antas, Paulo Renato Zuquim |
| description | Tuberculosis (TB) has been a major public health problem worldwide, and the Bacillus Calmette-Guérin (BCG) vaccine is the only available vaccine against this disease. The BCG vaccine is no longer a single organism; it consists of diverse strains. The early-shared strains of the BCG vaccine are stronger immunostimulators than the late-shared strains. In this study, we have employed a simple in vitro human model to broadly evaluate the differences among four widely used BCG vaccines during the characterization of strain-specific host immune responses. In general, the BCG Moreau vaccine generated a higher inflammatory cytokine profile and lower TGF-β levels compared with the Russia, Pasteur, and Danish strains in the context of early sensitization with TB; however, no changes were observed in the IL-23 levels between infected and noninfected cultures. Unsurprisingly, the BCG vaccines provided different features, and the variances among those strains may influence the activation of infected host cells, which ultimately leads to distinct protective efficacy to tackle TB. |
| doi_str_mv | 10.1080/21645515.2021.1989913 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_21645515_2021_1989913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b4d46fb797664b959a321b2956b6029b</doaj_id><sourcerecordid>2597489918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-422bfd80875b47c59c9399f1660ff5cde3f6ee93f7e8d989014e558d8f42a8763</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIVqU_AeQjh-4SO7Zjc0DAAqVSEQgViZs1ceyuSxIH29nV_hr-Kt6PrugFX2Y08-bNeOYVxXNcznEpylcEc8oYZnNSEjzHUkiJq0fF6TY-Y4z-fHz0MTspzmO8K_OrS0I5f1qcVLTmXHBxWvy5cb1BySMLOtulQWPw3sbXO__94hJ98cHAhFagtRt26d4nE1GcRhOcD8gNtoO-h-TDBulN8r8OOOs6k7No5VLwaL00A9K-HyGYFq1dWqLvU4wOLtA3iMlM4QLB0KIPMLi4RDEFcEN8Vjyx0EVzfrBnxY9PH28Wn2fXXy-vFu-uZ5pVNM0oIY1tRSlq1tBaM6llJaXFnJfWMt2aynJjZGVrI9q8rhJTw5hohaUERM2rs-Jqz9t6uFNjcD2EjfLg1C7gw62CkJzujGpoS7ltapl3SBvJJFQEN0Qy3vCSyCZzvdlzjVPTm1abIf-le0D6MDO4pbr1KyUkJZTUmeDlgSD435OJSfUuatN1MBg_RUWYrOn25iJD2R6qg48xGHtsg0u11Yq614raakUdtJLrXvw747HqXhkZ8HYPyOf1oYe1D12rEmw6H2yAQbuoqv_3-AvBG9C6</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2597489918</pqid></control><display><type>article</type><title>Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>da Silva, Andreon Santos Machado ; Albuquerque, Lawrence Henrique Paz ; de Ponte, Carlos Germano Garrido ; de Almeida, Matheus Rogério ; de Faria, Sandra Elizabete Ribeiro ; Ribeiro, Mariana da Silva ; Pereira, Evelyn Nunes Goulart da Silva ; Antas, Paulo Renato Zuquim</creator><creatorcontrib>da Silva, Andreon Santos Machado ; Albuquerque, Lawrence Henrique Paz ; de Ponte, Carlos Germano Garrido ; de Almeida, Matheus Rogério ; de Faria, Sandra Elizabete Ribeiro ; Ribeiro, Mariana da Silva ; Pereira, Evelyn Nunes Goulart da Silva ; Antas, Paulo Renato Zuquim</creatorcontrib><description>Tuberculosis (TB) has been a major public health problem worldwide, and the Bacillus Calmette-Guérin (BCG) vaccine is the only available vaccine against this disease. The BCG vaccine is no longer a single organism; it consists of diverse strains. The early-shared strains of the BCG vaccine are stronger immunostimulators than the late-shared strains. In this study, we have employed a simple in vitro human model to broadly evaluate the differences among four widely used BCG vaccines during the characterization of strain-specific host immune responses. In general, the BCG Moreau vaccine generated a higher inflammatory cytokine profile and lower TGF-β levels compared with the Russia, Pasteur, and Danish strains in the context of early sensitization with TB; however, no changes were observed in the IL-23 levels between infected and noninfected cultures. Unsurprisingly, the BCG vaccines provided different features, and the variances among those strains may influence the activation of infected host cells, which ultimately leads to distinct protective efficacy to tackle TB.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2021.1989913</identifier><identifier>PMID: 34766868</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>BCG Vaccine ; CG Vaccine; strains ; cytokine ; Cytokines ; Denmark ; Humans ; Licensed Vaccines – Short Report ; Mycobacterium bovis ; Mycobacterium bovis BCG Moreau ; Mycobacterium bovis BCG Russia ; Russia ; Tuberculosis ; Tuberculosis - prevention & control</subject><ispartof>Human vaccines & immunotherapeutics, 2022-12, Vol.18 (1), p.1989913-1989913</ispartof><rights>2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021</rights><rights>2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-422bfd80875b47c59c9399f1660ff5cde3f6ee93f7e8d989014e558d8f42a8763</citedby><cites>FETCH-LOGICAL-c534t-422bfd80875b47c59c9399f1660ff5cde3f6ee93f7e8d989014e558d8f42a8763</cites><orcidid>0000-0003-0599-5564 ; 0000-0002-7670-2047 ; 0000-0001-5915-0888 ; 0000-0002-3952-4683 ; 0000-0002-5254-8882 ; 0000-0002-5664-3764 ; 0000-0001-5511-7036 ; 0000-0002-6168-9185</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942427/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942427/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34766868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>da Silva, Andreon Santos Machado</creatorcontrib><creatorcontrib>Albuquerque, Lawrence Henrique Paz</creatorcontrib><creatorcontrib>de Ponte, Carlos Germano Garrido</creatorcontrib><creatorcontrib>de Almeida, Matheus Rogério</creatorcontrib><creatorcontrib>de Faria, Sandra Elizabete Ribeiro</creatorcontrib><creatorcontrib>Ribeiro, Mariana da Silva</creatorcontrib><creatorcontrib>Pereira, Evelyn Nunes Goulart da Silva</creatorcontrib><creatorcontrib>Antas, Paulo Renato Zuquim</creatorcontrib><title>Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Tuberculosis (TB) has been a major public health problem worldwide, and the Bacillus Calmette-Guérin (BCG) vaccine is the only available vaccine against this disease. The BCG vaccine is no longer a single organism; it consists of diverse strains. The early-shared strains of the BCG vaccine are stronger immunostimulators than the late-shared strains. In this study, we have employed a simple in vitro human model to broadly evaluate the differences among four widely used BCG vaccines during the characterization of strain-specific host immune responses. In general, the BCG Moreau vaccine generated a higher inflammatory cytokine profile and lower TGF-β levels compared with the Russia, Pasteur, and Danish strains in the context of early sensitization with TB; however, no changes were observed in the IL-23 levels between infected and noninfected cultures. Unsurprisingly, the BCG vaccines provided different features, and the variances among those strains may influence the activation of infected host cells, which ultimately leads to distinct protective efficacy to tackle TB.</description><subject>BCG Vaccine</subject><subject>CG Vaccine; strains</subject><subject>cytokine</subject><subject>Cytokines</subject><subject>Denmark</subject><subject>Humans</subject><subject>Licensed Vaccines – Short Report</subject><subject>Mycobacterium bovis</subject><subject>Mycobacterium bovis BCG Moreau</subject><subject>Mycobacterium bovis BCG Russia</subject><subject>Russia</subject><subject>Tuberculosis</subject><subject>Tuberculosis - prevention & control</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk1v1DAQjRCIVqU_AeQjh-4SO7Zjc0DAAqVSEQgViZs1ceyuSxIH29nV_hr-Kt6PrugFX2Y08-bNeOYVxXNcznEpylcEc8oYZnNSEjzHUkiJq0fF6TY-Y4z-fHz0MTspzmO8K_OrS0I5f1qcVLTmXHBxWvy5cb1BySMLOtulQWPw3sbXO__94hJ98cHAhFagtRt26d4nE1GcRhOcD8gNtoO-h-TDBulN8r8OOOs6k7No5VLwaL00A9K-HyGYFq1dWqLvU4wOLtA3iMlM4QLB0KIPMLi4RDEFcEN8Vjyx0EVzfrBnxY9PH28Wn2fXXy-vFu-uZ5pVNM0oIY1tRSlq1tBaM6llJaXFnJfWMt2aynJjZGVrI9q8rhJTw5hohaUERM2rs-Jqz9t6uFNjcD2EjfLg1C7gw62CkJzujGpoS7ltapl3SBvJJFQEN0Qy3vCSyCZzvdlzjVPTm1abIf-le0D6MDO4pbr1KyUkJZTUmeDlgSD435OJSfUuatN1MBg_RUWYrOn25iJD2R6qg48xGHtsg0u11Yq614raakUdtJLrXvw747HqXhkZ8HYPyOf1oYe1D12rEmw6H2yAQbuoqv_3-AvBG9C6</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>da Silva, Andreon Santos Machado</creator><creator>Albuquerque, Lawrence Henrique Paz</creator><creator>de Ponte, Carlos Germano Garrido</creator><creator>de Almeida, Matheus Rogério</creator><creator>de Faria, Sandra Elizabete Ribeiro</creator><creator>Ribeiro, Mariana da Silva</creator><creator>Pereira, Evelyn Nunes Goulart da Silva</creator><creator>Antas, Paulo Renato Zuquim</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0599-5564</orcidid><orcidid>https://orcid.org/0000-0002-7670-2047</orcidid><orcidid>https://orcid.org/0000-0001-5915-0888</orcidid><orcidid>https://orcid.org/0000-0002-3952-4683</orcidid><orcidid>https://orcid.org/0000-0002-5254-8882</orcidid><orcidid>https://orcid.org/0000-0002-5664-3764</orcidid><orcidid>https://orcid.org/0000-0001-5511-7036</orcidid><orcidid>https://orcid.org/0000-0002-6168-9185</orcidid></search><sort><creationdate>20221231</creationdate><title>Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains</title><author>da Silva, Andreon Santos Machado ; Albuquerque, Lawrence Henrique Paz ; de Ponte, Carlos Germano Garrido ; de Almeida, Matheus Rogério ; de Faria, Sandra Elizabete Ribeiro ; Ribeiro, Mariana da Silva ; Pereira, Evelyn Nunes Goulart da Silva ; Antas, Paulo Renato Zuquim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-422bfd80875b47c59c9399f1660ff5cde3f6ee93f7e8d989014e558d8f42a8763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>BCG Vaccine</topic><topic>CG Vaccine; strains</topic><topic>cytokine</topic><topic>Cytokines</topic><topic>Denmark</topic><topic>Humans</topic><topic>Licensed Vaccines – Short Report</topic><topic>Mycobacterium bovis</topic><topic>Mycobacterium bovis BCG Moreau</topic><topic>Mycobacterium bovis BCG Russia</topic><topic>Russia</topic><topic>Tuberculosis</topic><topic>Tuberculosis - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>da Silva, Andreon Santos Machado</creatorcontrib><creatorcontrib>Albuquerque, Lawrence Henrique Paz</creatorcontrib><creatorcontrib>de Ponte, Carlos Germano Garrido</creatorcontrib><creatorcontrib>de Almeida, Matheus Rogério</creatorcontrib><creatorcontrib>de Faria, Sandra Elizabete Ribeiro</creatorcontrib><creatorcontrib>Ribeiro, Mariana da Silva</creatorcontrib><creatorcontrib>Pereira, Evelyn Nunes Goulart da Silva</creatorcontrib><creatorcontrib>Antas, Paulo Renato Zuquim</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>da Silva, Andreon Santos Machado</au><au>Albuquerque, Lawrence Henrique Paz</au><au>de Ponte, Carlos Germano Garrido</au><au>de Almeida, Matheus Rogério</au><au>de Faria, Sandra Elizabete Ribeiro</au><au>Ribeiro, Mariana da Silva</au><au>Pereira, Evelyn Nunes Goulart da Silva</au><au>Antas, Paulo Renato Zuquim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2022-12-31</date><risdate>2022</risdate><volume>18</volume><issue>1</issue><spage>1989913</spage><epage>1989913</epage><pages>1989913-1989913</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Tuberculosis (TB) has been a major public health problem worldwide, and the Bacillus Calmette-Guérin (BCG) vaccine is the only available vaccine against this disease. The BCG vaccine is no longer a single organism; it consists of diverse strains. The early-shared strains of the BCG vaccine are stronger immunostimulators than the late-shared strains. In this study, we have employed a simple in vitro human model to broadly evaluate the differences among four widely used BCG vaccines during the characterization of strain-specific host immune responses. In general, the BCG Moreau vaccine generated a higher inflammatory cytokine profile and lower TGF-β levels compared with the Russia, Pasteur, and Danish strains in the context of early sensitization with TB; however, no changes were observed in the IL-23 levels between infected and noninfected cultures. Unsurprisingly, the BCG vaccines provided different features, and the variances among those strains may influence the activation of infected host cells, which ultimately leads to distinct protective efficacy to tackle TB.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>34766868</pmid><doi>10.1080/21645515.2021.1989913</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0599-5564</orcidid><orcidid>https://orcid.org/0000-0002-7670-2047</orcidid><orcidid>https://orcid.org/0000-0001-5915-0888</orcidid><orcidid>https://orcid.org/0000-0002-3952-4683</orcidid><orcidid>https://orcid.org/0000-0002-5254-8882</orcidid><orcidid>https://orcid.org/0000-0002-5664-3764</orcidid><orcidid>https://orcid.org/0000-0001-5511-7036</orcidid><orcidid>https://orcid.org/0000-0002-6168-9185</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2022-12, Vol.18 (1), p.1989913-1989913 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_21645515_2021_1989913 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | BCG Vaccine CG Vaccine strains cytokine Cytokines Denmark Humans Licensed Vaccines – Short Report Mycobacterium bovis Mycobacterium bovis BCG Moreau Mycobacterium bovis BCG Russia Russia Tuberculosis Tuberculosis - prevention & control |
| title | Time to face the proofs: the BCG Moreau vaccine promotes superior inflammatory cytokine profile in vitro when compared with Russia, Pasteur, and Danish strains |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T09%3A31%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Time%20to%20face%20the%20proofs:%20the%20BCG%20Moreau%20vaccine%20promotes%20superior%20inflammatory%20cytokine%20profile%20in%20vitro%20when%20compared%20with%20Russia,%20Pasteur,%20and%20Danish%20strains&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=da%20Silva,%20Andreon%20Santos%20Machado&rft.date=2022-12-31&rft.volume=18&rft.issue=1&rft.spage=1989913&rft.epage=1989913&rft.pages=1989913-1989913&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2021.1989913&rft_dat=%3Cproquest_cross%3E2597489918%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2597489918&rft_id=info:pmid/34766868&rft_doaj_id=oai_doaj_org_article_b4d46fb797664b959a321b2956b6029b&rfr_iscdi=true |